Best Life Sciences Companies in Carlsbad, United States

Provider of rapid point-of-care diagnostic test solutions. It offers FebriDx a rapid, fingerstick blood test intended to help differentiate between bacterial vs non-bacterial acute respiratory infections and ViraDx a rapid POC test that can simultaneously test for respiratory viruses like COVID-19 and Influenza A/B.

Developer of therapeutics for the treatments of adult and pediatric cancer. It offers QN-302 for G4-targeted tumors, Pan-RAS for advanced solid tumors and QN-247 for Nucleolin- expressing malagnancies.

Funding rounds

• Sep 2025Post IPO$41M
• Jul 2025Post IPO$4.5M
• Nov 2024Post IPO$5.1M

Founders & team

Michael PoirierFounder & CEO

Investors

Faraday Future, Sign Global, Sequoia Capital, IDG Capital, Circle

Developer of therapeutics for gastrointestinal complications. The company's lead candidate GT-2108 is a microbiota-activated PDE4 inhibitor prodrug for the treatment of moderate-to-severe ulcerative colitis. Other drug is GT-1908 for fibrostenotic crohn’s disease.

Funding rounds

• Jan 2026Post IPO$500K
• May 2024Post IPO$4M
• Dec 2022Post IPO—
• May 2022Post IPO$2.4M

Founders & team

Thomas HallamCEO

Investors

Yumaregional, HHS, Crohn's & Colitis Foundation, Business Innovation Network

Tech stack

AccessibeCloudflareCookieyesDiviFlywheelGoogle Analytics

Digital molecular biology analytics for disease management The proprietary platform is designed to be used in conjunction with existing qPCR instruments and to increase their multiplexing capabilities. Using their proprietary cloud-based software and assay design.

Innovating molecular diagnostics for better health and saving lives. This life sciences company is dedicated to alleviating suffering and improving health through innovative molecular diagnostics for infectious and non-communicable diseases. Focused on discovering, developing, and commercializing innovative DNA/RNA based diagnostic technologies and products, they provide cutting-edge tools for molecular analysis. Their expertise lies in RNA/DNA molecular diagnostics, point-of-care diagnostics offering rapid results, infectious disease detection for effective control, and cancer diagnostics for precise treatment planning. They develop and commercialize novel diagnostics based on innovative nucleic acid technologies. Their key differentiators include minimal sample preparation, amplification without PCR, low-cost solutions, and point-of-care testing. They are committed to improving healthcare worldwide through high-quality, reliable diagnostics.

Funding rounds

• Jul 2025Grant (prize money)$1.6M
• Apr 2025Grant (prize money)$2.3M
• Sep 2023Grant (prize money)$1.3M
• Jan 2021Grant (prize money)$999.9K

Founders & team

HyunDae ChoFounder & CEO

Investors

National Science Foundation, HHS

JumpCode provides technology for depleting unwanted nucleic acid. The CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to deplete unwanted nucleic acid molecules from sequencing libraries. The applications of the technology include host organism depletion, ribosomal RNA depletion, repetitive sequence depletion, allele-specific depletion, and others. The patented CRISPRclean technology allows the researcher to remove unwanted regions. The company provides products for RNA depletion suing the rRNA depletion kits or DNA depletion using the companies DNA Depletion kit.

Active Motif develops and distributes tools that enable epigenetics and gene regulation research. It offers products in the areas of gene regulation, epigenetics and chromatin, antibodies, protein detection and quantitation, recombinant proteins and enzymes, fluorescence, and bioinformatics. The company also provides antibodies, fluorescent dyes, kits, recombinant proteins, reporter assays and epigenetic services that include contract research services. It serves life science industries, and clinical and pharmaceutical/drug discovery communities.

Funding rounds

• Apr 2025Grant (prize money)$314.3K
• Dec 2023Grant (prize money)$314.3K
• Sep 2018Grant (prize money)$2.1M
• Sep 2017Grant (prize money)$225K

Founders & team

Joe FernandezFounder

Investors

HHS, National Science Foundation, Broadoak Capital Partners

Tech stack

Apple Icloud MailCart FunctionalityCdnjsCloudflareFullstoryGoogle Analytics

Developer of a neurostimulation system for managing intractable chronic pain. The company offers Nalu neurostimulation system which is a micro-implantable pulse generator is used for Spinal Cord Stimulation and Peripheral Nerve Stimulation. The device uses gentle electrical impulses to interrupt pain signals.

Funding rounds

• Dec 2023Series E$115.1M
• Oct 2022Conventional Debt$45M
• Feb 2022Series B$104M
• Jul 2015Series A$11.9M

Founders & team

Keegan HarperFounder

Investors

Runway Growth Capital, Novo Holdings, Gilde Healthcare, MVM, Endeavour Vision, Decheng Capital

Tech stack

Animate.CssApple Icloud MailCloudflareCloudflare Bot ManagementCore-JsExactmetrics

Developer of cell-based therapies for the treatment of cancer, eye disease, and spinal disorders. The company is using pluripotent and progenitor cells to develop terminally differentiated human cells for regenerative therapies. The cell therapy programs developed are OpRegen, which is a retinal pigment epithelium cells for dry age-related macular degeneration, OPC1 (oligodendrocyte progenitor cells for spinal cord injuries), and VAC2 that is an antigen-presenting dendritic cell for cancer immunotherapy. The company is developing a cell delivery device called Renevia for whole adipose tissue cell-assisted lipotransfer (CAL) in facial volume restoration procedures.

Funding rounds

• Apr 2024Grant (prize money)—
• May 2023Grant (prize money)$50K
• Sep 2020Grant (prize money)$576.4K
• Aug 2020Post IPO$24.6M

Founders & team

Brian CulleyCEO

Investors

Juvenescence, Israel Innovation Authority, State of California, HHS, SBIR, NIH

Tech stack

AccessibeCloudflareCloudflare Browser InsightsDocusignGoogle AnalyticsGoogle Font Api

Develops disease-modifying therapies for degenerative disorders

Funding rounds

• Jan 2021Series B$125M
• Jun 2020Series A$45.5M
• Jul 2019Grant (prize money)$225K
• Jun 2019Grant (prize money)$435.3K

Founders & team

Aseem AnsariCo-FounderPratik ShahChairman and CEO

Investors

SR One, Quan Capital, WestRiver Group, Logos, BlackRock, RA Capital Management

Tech stack

AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch

Developer of molecular biology tools for gene expression. The company has developed a novel product for targeted sequencing called TempO-Seq, a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. TempO-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. Sample barcoding, together with sequencing short fragments of each gene, enables pooling up to 6,144 samples in one sequencing run.

Developer of xenon chloride excimer lasers for treatment of skin and vascular diseases. Their flagship product, the PHAROS EX-308 delivers monochromatic 308 nm UVB rays has applications in the treatment of skin diseases like psoriasis, vitiligo, atopic dermatitis, and leukoderma. Also, has a DABRA minimally-invasive excimer laser and disposable catheter system that is used for endovascular treatment of vascular blockages.